Cargando…

Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study

Detalles Bibliográficos
Autores principales:	Talmage, Garrick D., Coppes, Oscar J. M., Javed, Adil, Bernard, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436866/ https://www.ncbi.nlm.nih.gov/pubmed/28542604 http://dx.doi.org/10.1371/journal.pone.0178338

Ejemplares similares

Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study
por: Talmage, Garrick D., et al.
Publicado: (2017)

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment
por: Koskimäki, Fredrika, et al.
Publicado: (2018)

Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2010)

Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug
por: Javed, Adil, et al.
Publicado: (2016)

Correction: Optical coherence tomography (OCT) in unconscious and systemically unwell patients using a mobile OCT device: a pilot study
Publicado: (2020)

Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis
Publicado: (2015)

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Correction to: Reducing New Persistent Opioid Use After Surgery: a Review of Interventions
por: Burns, Stacey, et al.
Publicado: (2021)

Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
por: Persaud, Stephen P., et al.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
por: Gobbi, Claudio, et al.
Publicado: (2013)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings
por: Mattioli, Flavia, et al.
Publicado: (2015)

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
por: Perumal, Jai, et al.
Publicado: (2023)

Correction: Embryonic Stem Cells Markers SOX2, OCT4 and Nanog Expression and Their Correlations with Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma
por: Luo, Weiren, et al.
Publicado: (2013)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2023)

Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy
por: Clausi, Valeria, et al.
Publicado: (2015)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial
por: Schultz, Timothy J., et al.
Publicado: (2021)

Publisher Correction: Human mid-trimester amniotic fluid (stem) cells lack expression of the pluripotency marker OCT4A
por: Vlahova, Filipa, et al.
Publicado: (2020)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
por: Iaffaldano, Pietro, et al.
Publicado: (2012)

Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment
por: Diaz‑Galvan, Patricia, et al.
Publicado: (2023)

Correction to: Image registration in dynamic renal MRI—current status and prospects
por: Zöllner, Frank G., et al.
Publicado: (2020)

Correction: An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy
por: Thompson, Dorothy A., et al.
Publicado: (2021)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Clinical and neuroimaging findings in MOGAD–MRI and OCT
por: Bartels, Frederik, et al.
Publicado: (2021)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Pulmonary eosinophilia associated to treatment with natalizumab
por: Curto, Elena, et al.
Publicado: (2016)

Identification of Peptide Mimotope Ligands for Natalizumab
por: Ruff, Laura E., et al.
Publicado: (2018)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Author Correction: Neuroimaging and cognitive correlates of retinal Optical Coherence Tomography (OCT) measures at late middle age in a twin sample
por: Moran, Chris, et al.
Publicado: (2022)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3h5e749h4f3ldpjg611m34174n